EX-10.3 - Retention Agreement, dated as of December 20, 2012



 Exhibit 10.3 
 RETENTION AGREEMENT 
 This RETENTION AGREEMENT (this “Agreement”)
is made and entered into as of the 20th day of December, 2012 (the “Effective Date”) by and between BioMimetic Therapeutics, Inc. (including its successors, the “Company”) and Larry Bullock (the
“Executive” and, with the Company, the “Parties”). 
 WHEREAS, the Company has entered into a
merger agreement dated November 19, 2012 by and among Wright Medical Group, Inc., a Delaware corporation (the “Parent”), Achilles Merger Subsidiary, Inc., a Delaware corporation and a direct wholly owned subsidiary of the
Parent, Achilles Acquisition Subsidiary, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Parent, and the Company (as amended from time to time, the “Merger Agreement”); and 

WHEREAS, the Company desires to retain the Executive in the Executive’s current position and the Executive desires to remain so
employed from the Effective Date through and for a limited period following the Closing (as such term is defined in the Merger Agreement); and 
 WHEREAS, the Parties desire to set forth in this Agreement the terms and conditions under which the Executive will be eligible to receive certain payments in consideration of his continued employment with
the Company through and following the Closing. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual
promises, terms, provisions and conditions set forth in this Agreement, the Parties hereby agree as follows: 
 1. Transition
Assistance Award. If the Executive remains continuously employed by the Company from the date hereof through the Closing Date (as such term is defined in the Merger Agreement), the Executive will be entitled to receive an amount equal to $40,000
payable in a single lump sum within 10 business days following the Closing Date. 
 2. Severance Enhancement. If the
Executive remains continuously employed by the Company from the date hereof through the two-month anniversary of the Closing Date, the Executive’s entitlement to severance under the Executive’s Employment Agreement with the Company dated
as of July 17, 2012 will be enhanced by the addition of four months of salary continuation payments commencing the month following the last month of salary continuation payments payable under that Employment Agreement, such additional salary
continuation payments to be paid in accordance with the Company’s normal and customary payroll practices at the rate of the Executive’s annual base salary as in effect on the two-month anniversary of the Closing Date. 

3. Payment of 2012 Bonus. The Executive will be paid his bonus for the 2012 fiscal year in the amount of $46,510 not later than
December 31, 2012, subject to and conditioned upon the Executive remaining continuously employed by the Company from the date hereof through the date of payment. 







 4. Payment of Accrued Vacation. On the Closing Date, the Executive will be paid an
amount in a single lump sum equal to his accrued but unused vacation as of the Closing Date, subject to and conditioned upon the Executive remaining continuously employed by the Company from the date hereof through the Closing Date. 

5. Assumption of Options. Options to purchase shares of common stock of the Company held by the Executive having an exercise price
less than $13.00 that are outstanding and unexercised as of the Closing will be assumed by the Parent in accordance with the terms of the Merger Agreement. 
 6. Withholding. All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law. 

7. Assignment. Neither the Company nor the Executive may make any assignment of this Agreement or any interest herein, by
operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without the consent of the Executive in the event that the Company shall
hereafter effect a reorganization, or consolidate with, or merge into, any other Person or transfer all or substantially all of its properties, stock, or assets to any other Person. For purposes of this Section 7, the term
“Person” means an individual, a corporation, an association, a partnership, an estate, a trust and any other entity or organization and includes all persons and entities directly or indirectly controlling, controlled by or under common
control with the Company, where control may be by management authority, equity interest, contract, debt or other financing. This Agreement shall inure to the benefit of and be binding upon the Company and the Executive, their respective successors,
executors, administrators, heirs and permitted assigns. 
 8. Severability. If any portion or provision of this Agreement
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared
illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

9. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving Party. The
failure of either Party to require the performance of any term or obligation of this Agreement, or the waiver by either Party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a
waiver of any subsequent breach. 
 10. Notices. Any and all notices, requests, demands and other communications provided
for by this Agreement shall be in writing and shall be effective when delivered in person, consigned to a reputable national courier service for next day or next business day delivery or deposited in the United States mail, postage prepaid,
registered or certified, and addressed to the Executive at his last known address on the books of the Company or, in the case of the Company, at its principal place of business, attention of the board of directors, or to such other address as either
Party may specify by notice to the other actually received. 

  
 -2-









 11. Entire Agreement. This Agreement constitutes the entire agreement between the
Parties with respect to the subject matter herein and supersedes and terminates all prior communications, agreements and understandings, written or oral, including any employment agreement, with respect to any payments payable pursuant to
Sections 1, 2, 3 and 4 of this Agreement. 
 12. No Contract of Employment. This agreement is not intended to and
does not confer on the Executive or otherwise give rise to any right to continue in employment with the Company for any definite period of time or in any particular position. 
 13. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by an expressly authorized representative of the Company’s board of directors.

 14. Headings. The headings and captions in this Agreement are for convenience only and in no way define or describe
the scope or content of any provision of this Agreement. 
 15. Counterparts. This Agreement may be executed in one or
more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument. 

16. Governing Law. This contract shall be construed and enforced under, and be governed in all respects by the laws of, the State
of Delaware, without regard to the conflict of laws principles thereof. 
 [The remainder of this page has been left
blank intentionally.] 

  
 -3-









 INTENDING TO BE LEGALLY BOUND, the Executive and the Company, by its duly authorized
representative, have executed this Agreement, as a sealed instrument as of the Effective Date. 
  

							
	THE EXECUTIVE	 		 	BIOMIMETIC THERAPEUTICS, INC.
			
	 /s/ Larry Bullock
	 		 	 /s/ Samuel E. Lynch

	Larry Bullock	 		 	By:	 	Samuel E. Lynch
		 		 	Title:	 	President and Chief Executive Officer


  
 [Retention
Agreement Signature Page]